European Association of Nuclear Medicine (EANM) (@eanm.org)

Theranostic Radiopharma in Europe in 2025: an IHI Thera4Care Consortium Public Short Survey Dear Responders, thanks to join this first IHI Thera4Care Consortium Public Short Survey, focused on the Theranostic Radiopharmaceuticals in Europe in 2025! The IHI Thera4Care project is the largest EU-funded and public-private European initiative on Theranostics, with >25M budget, 27 partners and 15 countries represented, which aims to revolutionise precision oncology and establish Europe as a global leader in theranostics in the next 5 years (www.thera4care.eu). Thera4Care brings together academic centres, healthcare providers, SMEs, and industry stakeholders to create a collaborative European ecosystem and to support healthcare system readiness for theranostics. With this first IHI Thera4Care Consortium Public Short Survey, we aim to have a comprehensive and large overview about the status of Theranostic Radiopharmaceuticals in Europe in 2025, in order to better understand further issues about regulation, production, research and clinics in the ongoing project. We are glad to open this Short Survey to a broad and qualified audience of professionals! Thank you for your time and support. dr. Salvatore Annunziata, Scientific Coordinator, on behalf of the IHI Thera4Care Consortium and Leaders Thera4Care is funded by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101172788. The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, EuropaBio, MedTech Europe, Vaccines Europe, Atley Solutions, Curasight, Dosisoft, Minerva Imaging, Perspective Therapeutics, and Terthera. https://docs.google.com/forms/d/e/1FAIpQLSfozRygDKyODvwcBqbBbOJaRz-JfrI-1-ZMhRiewObrClRQ_Q/viewform